Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 13;17(1):84.
doi: 10.1186/s12920-024-01866-y.

Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics

Bing Cao  1   2   3   4 , Chenbo Sun  1   2   3 , Rui Bi  1   2   3 , Zebing Liu  1   2   3   5 , Yijun Jia  1   2   3 , Wenli Cui  1   2   3   6 , Menghong Sun  1   2   3 , Baohua Yu  1   2   3 , Xiaoqiu Li  1   2   3 , Xiaoyan Zhou  7   8   9
Affiliations

Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics

Bing Cao et al. BMC Med Genomics. .

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL), an aggressive and heterogenic malignant entity, is still a challenging clinical problem, since around one-third of patients are not cured with primary treatment. Next-generation sequencing (NGS) technologies have revealed common genetic mutations in DLBCL. We devised an NGS multi-gene panel to discover genetic features of Chinese nodal DLBCL patients and provide reference information for panel-based NGS detection in clinical laboratories.

Methods: A panel of 116 DLBCL genes was designed based on the literature and related databases. We analyzed 96 Chinese nodal DLBCL biopsy specimens through targeted sequencing.

Results: The most frequently mutated genes were KMT2D (30%), PIM1 (26%), SOCS1 (24%), MYD88 (21%), BTG1 (20%), HIST1H1E (18%), CD79B (18%), SPEN (17%), and KMT2C (16%). SPEN (17%) and DDX3X (6%) mutations were highly prevalent in our study than in Western studies. Thirty-three patients (34%) were assigned as genetic classification by the LymphGen algorithm, including 12 cases MCD, five BN2, seven EZB, seven ST2, and two EZB/ST2 complex. MYD88 L265P mutation, TP53 and BCL2 pathogenic mutations were unfavorable prognostic biomarkers in DLBCL.

Conclusions: This study presents the mutation landscape in Chinese nodal DLBCL, highlights the genetic heterogeneity of DLBCL and shows the role of panel-based NGS to prediction of prognosis and potential molecular targeted therapy in DLBCL. More precise genetic classification needs further investigations.

Keywords: Diffuse large B-cell lymphoma; Genetic subtype; Mutation; Next-generation sequencing; Targeted sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
OncoPrint of non-silent mutations for the top genes in 96 Chinese DLBCL patients. Genes affected by non-silent mutations in at least 5 DLBCL samples (5% of cases) are listed. These mutations were annotated by OncoKB in cBioPortal on February 3, 2022. Each row represents a gene, and each column represents a DLBCL sample. Orange squares: inframe mutation (unknown significance); dark green squares: missense mutation (putative driver); light green squares: missense mutation (unknown significance); black squares: truncating mutation (putative driver); blue gray squares: truncating mutation (unknown significance); gray bars: no alterations. Nonsense, frameshift and splice site mutations are referred to as truncating mutations in the figure
Fig. 2
Fig. 2
Schematic diagrams summarizing the mutations identified in SPEN (a) and DDX3X (b). The schematic diagrams were performed with the aid of MutationMapper in cBioPortal. Green circles: missense mutation; black circles: truncating mutation. Nonsense, frameshift and splice site mutations are referred to as truncating mutations in the figure
Fig. 3
Fig. 3
Genetic subtypes of DLBCL. a Prevalence of genetic subtypes of DLBCL classified by the LymphGen tool. b Prevalence of genetic subtypes in COO (Hans) subgroups
Fig. 4
Fig. 4
Kaplan–Meier curves for progression-free survival and overall survival of patients with DLBCL. a Survival analysis was performed on total patients according to BCL2 mutation status. b Survival analysis was performed on patients treated with R-CHOP according to the presence or absence of MYD88 L265P mutation
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2008.
    1. Li X, Li G, Gao Z, Zhou X, Zhu X. The relative frequencies of lymphoma subtypes in China: a nationwide study of 10002 cases by the Chinese lymphoma study group. Ann Oncol. 2011;224:141.
    1. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040–5. doi: 10.1182/blood-2010-03-276246. - DOI - PMC - PubMed
    1. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–1022. doi: 10.1016/S1470-2045(11)70235-2. - DOI - PubMed
    1. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498–505. doi: 10.1182/asheducation-2011.1.498. - DOI - PubMed

Publication types

MeSH terms

Substances